Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Equity Average (2016 - 2025)

Historic Equity Average for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $535.9 million.

  • Arrowhead Pharmaceuticals' Equity Average rose 33370.02% to $535.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $535.9 million, marking a year-over-year increase of 33370.02%. This contributed to the annual value of $347.2 million for FY2025, which is 4522.01% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Equity Average stood at $535.9 million for Q4 2025, which was up 33370.02% from $512.9 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Equity Average peaked at $603.3 million during Q2 2025, and registered a low of $123.6 million during Q4 2024.
  • Moreover, its 5-year median value for Equity Average was $420.0 million (2021), whereas its average is $400.8 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Equity Average tumbled by 4637.65% in 2024 and then surged by 33370.02% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Equity Average (Quarter) stood at $390.7 million in 2021, then grew by 4.27% to $407.4 million in 2022, then plummeted by 43.43% to $230.4 million in 2023, then plummeted by 46.38% to $123.6 million in 2024, then soared by 333.7% to $535.9 million in 2025.
  • Its last three reported values are $535.9 million in Q4 2025, $512.9 million for Q3 2025, and $603.3 million during Q2 2025.